Comparative Pharmacology
Head-to-head clinical analysis: DRYTEC versus MYFED.
Peer-Reviewed Evidence
Head-to-head clinical analysis: DRYTEC versus MYFED.
DRYTEC vs MYFED
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
Drytec is an antihistamine that selectively inhibits peripheral H1 receptors, reducing histamine-mediated allergic symptoms.
Pseudoephedrine is a sympathomimetic amine that acts as a decongestant by stimulating alpha-adrenergic receptors in the respiratory tract mucosa, causing vasoconstriction and reducing nasal congestion.
1-2 tablets (paracetamol 500 mg/pseudoephedrine 30 mg) orally every 4-6 hours; maximum 8 tablets per day.
500 mg orally twice daily with meals.
None Documented
None Documented
Terminal elimination half-life is approximately 3.5 to 4 hours in adults with normal renal function; may be prolonged in elderly or patients with renal impairment.
3-5 hours in adults with normal renal function; prolonged to 12-24 hours in severe renal impairment (CrCl <30 mL/min).
Renal excretion of unchanged drug accounts for approximately 65% of the administered dose; fecal/biliary elimination contributes about 35%.
Primarily renal (85-90% as unchanged drug) via glomerular filtration and tubular secretion; minor biliary/fecal excretion (5-10%).
Category C
Category C
Decongestant
Decongestant